Free Trial

Daiichi Sankyo (OTCMKTS:DSNKY) Shares Up 0.6% - Here's Why

Daiichi Sankyo logo with Medical background

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report)'s share price rose 0.6% during mid-day trading on Friday . The stock traded as high as $22.12 and last traded at $22.03. Approximately 179,839 shares were traded during mid-day trading, a decline of 18% from the average daily volume of 219,220 shares. The stock had previously closed at $21.90.

Wall Street Analysts Forecast Growth

Separately, Nomura Securities raised shares of Daiichi Sankyo to a "strong-buy" rating in a report on Friday, June 6th.

View Our Latest Stock Analysis on Daiichi Sankyo

Daiichi Sankyo Stock Performance

The stock's fifty day simple moving average is $24.34 and its 200-day simple moving average is $24.69. The company has a market capitalization of $43.16 billion and a price-to-earnings ratio of 22.12. The company has a current ratio of 2.53, a quick ratio of 1.85 and a debt-to-equity ratio of 0.06.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last announced its quarterly earnings results on Friday, April 25th. The company reported $0.30 EPS for the quarter. Daiichi Sankyo had a net margin of 15.65% and a return on equity of 17.92%. The firm had revenue of $3.40 billion for the quarter. Analysts predict that Daiichi Sankyo Co., Ltd. - Sponsored ADR will post 0.73 EPS for the current year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

Recommended Stories

Should You Invest $1,000 in Daiichi Sankyo Right Now?

Before you consider Daiichi Sankyo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.

While Daiichi Sankyo currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines